Neurelis
PrivateLast Round
Series D
Aug 26, 2022
Total Funding Raised
$350.9M
Company Overview
Neurelis operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series D round in August 2022.
Neurelis is a neuroscience company that develops and commercializes therapeutics for the treatment of epilepsy and other central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurelis Comparables
Compare Neurelis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aquestive Therapeutics Inc | 84% | |
| Crossject | 78% | |
| Shin Nippon Biomedical Laboratories Ltd | 74% |
For institutional investors. Book with your work email.
Neurelis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 26, 2022 | ||||
| Debt | Aug 11, 2021 | ||||
| Series D | Mar 10, 2021 | ||||
| Series D | Oct 21, 2020 | ||||
| Series C | Nov 8, 2018 | ||||
Series B | Jan 5, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neurelis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CMS Medical Venture Investment (HK) Limited | Series C |
| LYZZ Capital | Series C, Series B, Series A, Series D |
| Cormorant Asset Management | Series D |
| OrbiMed | Debt |
| HBM Healthcare Investments | Series D, Series C, Series B |
| Philos & Partners Ltd. | Series D |
| Cormorant Asset Management | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 38% MoM.
- Apr 23, 2026
Attending Epilepsy Awareness Day at Walt Disney World.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 10, 2026
Neurelis, Inc. is developing NRL-1049, previously known as BA-1049, an investigational Phase 1 Rho kinase inhibitor for treating cerebral cavernous malformations, a rare central nervous system disorder.
- attends_eventSep 10, 2026
Neurelis, Inc.'s Founder and CEO Craig Chambliss will give a keynote at the 14th Annual Outsourcing Clinical Trials (OCT) Southern California 2026 conference in California on Sep 15th–16th '26.
- is_developingSep 10, 2026
Neurelis, Inc. is developing investigational NRL-1049, previously known as BA-1049, a Phase 1 new chemical entity Rho kinase (ROCK) inhibitor for treating cerebral cavernous malformations, a rare central nervous system disorder.
For institutional investors. Book with your work email.
Neurelis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neurelis's valuation, stock price, and market status.
Is Neurelis a public or private company?
Neurelis is a private company.
What is the current stock price of Neurelis?
Neurelis is a private company, so its shares have no public market price. Caplight tracks Neurelis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neurelis worth (valuation)?
Valuation information for Neurelis is not publicly available.
Can I buy Neurelis stock?
Neurelis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neurelis's last funding round?
Neurelis's most recent funding round was Series D on August 26, 2022.
Who are the main investors in Neurelis?
Key investors in Neurelis include LYZZ Capital, HBM Healthcare Investments.
Will Neurelis IPO soon?
No public IPO plans have been announced for Neurelis.
How can I track Neurelis secondary market activity?
Caplight tracks bids, offers, and trades in Neurelis's shares on secondary markets.